Queen's University researchers have devised a new method of performing lab tests that can aid doctors to manage prostate cancer treatment.

It extends in supporting the cure by identifying a gene called PTEN that is associated with an aggressive group of prostate cancers.

The procedure lends a hand to cure via Fluorescence In-Situ Hybridisation (FISH) platform that uses DNA probes to analyse the three-dimensional space cancer cells, which is considered a superior way than PTEN loss in biopsies and tissue sections.

PTEN is found in nuclei of cancerous cells and is termed as the most effective cancer-causing tumor-suppressor genes.

According to Jeremy Squire, who worked with a team of researchers in the Department of Pathology and Molecular Medicine, variety of cancers including prostate, breast, and lung cancers can be cured by this method, and thus immense work is put in this similar field.